Stock JPH JERUSALEM PHARMACEUTICALS CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jerusalem Pharmaceuticals Co. Ltd.

Equities

JPH

PS2016112695

Pharmaceuticals

End-of-day quote Palestine Exchange
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
3.81 USD 0.00% Intraday chart for Jerusalem Pharmaceuticals Co. Ltd. -0.52% +0.26%
2023 Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 58.68 58.32 50.4 49.86 50.94 59.04
Enterprise Value (EV) 1 56.64 57.5 53.52 51.69 48.08 53.44
P/E ratio 9.57 x 9.52 x 9.42 x 13.4 x 7.72 x 8.23 x
Yield 3.07% 3.09% 3.57% 2.89% 4.24% 4.57%
Capitalization / Revenue 1.97 x 1.89 x 1.48 x 1.37 x 1.1 x 1.28 x
EV / Revenue 1.9 x 1.87 x 1.57 x 1.42 x 1.04 x 1.16 x
EV / EBITDA 7.98 x 7.93 x 7.79 x 8.69 x 4.83 x 5.07 x
EV / FCF -235 x 150 x -24 x -43.7 x 19.4 x 4.25 x
FCF Yield -0.43% 0.67% -4.17% -2.29% 5.16% 23.5%
Price to Book 1.21 x 1.2 x 0.96 x 0.84 x 0.77 x 0.92 x
Nbr of stocks (in thousands) 18,000 18,000 18,000 18,000 18,000 18,000
Reference price 2 3.260 3.240 2.800 2.770 2.830 3.280
Announcement Date 3/31/18 4/1/19 5/7/20 5/10/21 3/31/22 4/1/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 29.79 30.8 34.09 36.4 46.23 46.14
EBITDA 1 7.1 7.246 6.873 5.946 9.946 10.53
EBIT 1 5.665 5.664 5.194 4.012 7.985 8.808
Operating Margin 19.02% 18.39% 15.24% 11.02% 17.27% 19.09%
Earnings before Tax (EBT) 1 6.266 6.115 5.027 3.741 7.622 9.03
Net income 1 6.131 6.125 5.351 3.725 6.598 7.174
Net margin 20.58% 19.88% 15.7% 10.23% 14.27% 15.55%
EPS 2 0.3406 0.3403 0.2973 0.2070 0.3665 0.3985
Free Cash Flow 1 -0.2415 0.3841 -2.233 -1.182 2.482 12.57
FCF margin -0.81% 1.25% -6.55% -3.25% 5.37% 27.25%
FCF Conversion (EBITDA) - 5.3% - - 24.95% 119.34%
FCF Conversion (Net income) - 6.27% - - 37.62% 175.25%
Dividend per Share 2 0.1000 0.1000 0.1000 0.0800 0.1200 0.1500
Announcement Date 3/31/18 4/1/19 5/7/20 5/10/21 3/31/22 4/1/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 3.12 1.83 - -
Net Cash position 1 2.04 0.82 - - 2.86 5.6
Leverage (Debt/EBITDA) - - 0.4541 x 0.307 x - -
Free Cash Flow 1 -0.24 0.38 -2.23 -1.18 2.48 12.6
ROE (net income / shareholders' equity) 13.8% 11.9% 9.66% 6.3% 9.55% 10.8%
ROA (Net income/ Total Assets) 6.18% 5.67% 4.94% 3.38% 6.06% 6.45%
Assets 1 99.22 108 108.3 110.3 108.8 111.2
Book Value Per Share 2 2.700 2.700 2.900 3.300 3.690 3.570
Cash Flow per Share 2 0.1900 0.1400 0.0600 0.1100 0.3000 0.4300
Capex 1 1.7 1.39 1.57 1.46 2.19 0.68
Capex / Sales 5.71% 4.51% 4.6% 4.01% 4.74% 1.48%
Announcement Date 3/31/18 4/1/19 5/7/20 5/10/21 3/31/22 4/1/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
JERUSALEM PHARMACEUTICALS CO. LTD. Stock Jerusalem Pharmaceuticals Co. Ltd.
+0.26% 68.58M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JPH Stock
  4. Financials Jerusalem Pharmaceuticals Co. Ltd.